Natco Pharma is currently trading at Rs. 665.00, up by 3.80 points or 0.57% from its previous closing of Rs. 661.20 on the BSE.
The scrip opened at Rs. 652.50 and has touched a high and low of Rs. 677.30 and Rs. 652.50 respectively. So far 4752 shares were traded on the counter.
Natco Pharma The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1092.00 on 26-Jul-2021 and a 52 week low of Rs. 607.95 on 31-May-2022.
Last one week high and low of the scrip stood at Rs. 677.30 and Rs. 629.00 respectively. The current market cap of the company is Rs. 12070.68 crore.
The promoters holding in the company stood at 48.80%, while Institutions and Non-Institutions held 26.95% and 24.25% respectively.
The U.S. Food and Drug Administration (USFDA) has granted approval to Natco Pharma’s partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application (ANDA) for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.
Breckenridge and Natco are unable to make further comment regarding the launch date for the product, as that is confidential and cannot be disclosed at this time.
According to industry sales data, Jevtana Kit generated annual sales of $303 million during the twelve months ending May 2022.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
